Neuroblastoma: biology and staging

Area of Science:

• Pediatric oncology
• Cancer genetics
• Tumor biology

Background:

• Neuroblastoma is the most frequent extracranial childhood tumor in the US.
• Its clinical course is highly variable, influenced by age, stage, histology, and genetic factors like MYCN amplification.
• Tumor behavior ranges from spontaneous regression to progression despite treatment, reflecting underlying genetic heterogeneity.

Purpose of the Study:

• To review the biology of neuroblastoma.
• To discuss current and novel risk classification and staging systems.
• To outline preferred treatment strategies based on updated classifications.

Main Methods:

• Review of recent studies utilizing comparative genetic hybridization arrays, RNA expression microarrays, and genome-wide association studies.
• Inclusion of findings implicating the anaplastic lymphoma kinase gene in neuroblastoma tumorigenesis.
• Consideration of recommendations from the International Neuroblastoma Risk Group.

Main Results:

• Genetic heterogeneity is a key factor in neuroblastoma's varied clinical behavior.
• The anaplastic lymphoma kinase gene is implicated in familial and some sporadic neuroblastoma cases.
• New risk classifications and staging recommendations are available for improved patient management.

Conclusions:

• Understanding neuroblastoma's genetic basis is crucial for predicting its course.
• Updated risk stratification and staging are essential for tailoring treatment.
• Advances in molecular biology are refining diagnostic and therapeutic approaches for neuroblastoma.